Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 938

1.

A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.

Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Carson WH, Pikalov A, Assunção-Talbott S.

J Clin Psychiatry. 2009 Oct;70(10):1348-57. doi: 10.4088/JCP.09m05154yel.

PMID:
19906340
2.

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.

Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR.

Arch Gen Psychiatry. 2003 Jul;60(7):681-90.

PMID:
12860772
3.

Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.

Li H, Luo J, Wang C, Xie S, Xu X, Wang X, Yu W, Gu N, Kane JM.

Schizophr Res. 2014 Aug;157(1-3):112-9. doi: 10.1016/j.schres.2014.05.040. Epub 2014 Jul 1. Erratum in: Schizophr Res. 2014 Oct;159(1):256.

PMID:
24994555
4.
5.

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW.

J Clin Psychiatry. 2002 Sep;63(9):763-71.

PMID:
12363115
6.

The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.

Janicak PG, Glick ID, Marder SR, Crandall DT, McQuade RD, Marcus RN, Eudicone JM, Assunção-Talbott S.

J Clin Psychiatry. 2009 Jan;70(1):25-35. Epub 2008 Dec 2.

PMID:
19192472
7.

Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial.

Chan HY, Lin WW, Lin SK, Hwang TJ, Su TP, Chiang SC, Hwu HG.

J Clin Psychiatry. 2007 Jan;68(1):29-36.

PMID:
17284127
8.

A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).

Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA; Schizophrenia Trials Network.

Am J Psychiatry. 2011 Sep;168(9):947-56. doi: 10.1176/appi.ajp.2011.10111609. Epub 2011 Jul 18.

9.

Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.

Jin H, Shih PA, Golshan S, Mudaliar S, Henry R, Glorioso DK, Arndt S, Kraemer HC, Jeste DV.

J Clin Psychiatry. 2013 Jan;74(1):10-8. doi: 10.4088/JCP.12m08001. Epub 2012 Nov 27.

10.

A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.

Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH.

Am J Psychiatry. 2008 Nov;165(11):1432-41. doi: 10.1176/appi.ajp.2008.07061035. Epub 2008 Sep 2.

PMID:
18765484
11.

The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.

Glick ID, Mankoski R, Eudicone JM, Marcus RN, Tran QV, Assunção-Talbott S.

J Affect Disord. 2009 May;115(1-2):18-26. doi: 10.1016/j.jad.2008.12.017. Epub 2009 Feb 23.

PMID:
19230981
12.

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.

Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG.

Arch Gen Psychiatry. 1997 Jun;54(6):549-57.

PMID:
9193196
13.

Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.

Chen JX, Su YA, Bian QT, Wei LH, Zhang RZ, Liu YH, Correll C, Soares JC, Yang FD, Wang SL, Zhang XY.

Psychoneuroendocrinology. 2015 Aug;58:130-40. doi: 10.1016/j.psyneuen.2015.04.011. Epub 2015 Apr 24.

PMID:
25981348
14.

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.

Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A.

J Clin Psychiatry. 2007 Jun;68(6):843-53.

PMID:
17592907
15.

Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.

Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA.

J Clin Psychiatry. 2006 Jul;67(7):1093-103.

PMID:
16889453
16.

A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization.

Potkin SG, Gharabawi GM, Greenspan AJ, Mahmoud R, Kosik-Gonzalez C, Rupnow MF, Bossie CA, Davidson M, Burtea V, Zhu Y, Trivedi JK.

Schizophr Res. 2006 Jul;85(1-3):254-65. Epub 2006 Jun 21.

PMID:
16797162
17.

Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial.

Findling RL, McKenna K, Earley WR, Stankowski J, Pathak S.

J Child Adolesc Psychopharmacol. 2012 Oct;22(5):327-42. doi: 10.1089/cap.2011.0092.

PMID:
23083020
18.

Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.

Swainston Harrison T, Perry CM.

Drugs. 2004;64(15):1715-36. Review.

PMID:
15257633
19.

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.

Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T.

Schizophr Res. 2003 Jun 1;61(2-3):123-36.

PMID:
12729864
20.

Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study.

Keck PE, Orsulak PJ, Cutler AJ, Sanchez R, Torbeyns A, Marcus RN, McQuade RD, Carson WH; CN138-135 Study Group.

J Affect Disord. 2009 Jan;112(1-3):36-49. doi: 10.1016/j.jad.2008.05.014. Epub 2008 Oct 2.

PMID:
18835043

Supplemental Content

Support Center